

## FISH EQA in Pre-implantation genetic diagnosis

Ros Hastings PhD, FRCPath CEQA John Radcliffe Hospital Oxford UK

©2009

## **External Quality Assessment**

- · Sometimes referred to as proficiency testing
- An important component of an overall quality management system i.e. quality & competence
- Specific requirement for accreditation
- ISO 15189: 2007
- OECD Guidelines



CEGA

#### **OECD Guidelines 2007**

www.oecd.org/sti/biotechnology

- Recommendations on quality assurance in molecular genetic testing but also valid for other specialist genetic testing
- A number of principles and best practices
  - Promote internationally agreed minimum standards
  - EQA programmes that check the entire examination process including pre- and post-examination procedures
  - Quality policy that includes EQA
  - Implementation of corrective actions

^=	: 0 /	944	and the	-
ſ.	131			

### **Advantages of EQA**

- Comparison between laboratories helps to define good standards (best practice)
- Regular assessment compares laboratory performance against set standards
- Educates participants with the aim of improving the overall service to the user
- · Validates service quality
- Helps to build public confidence



CEQA STATE

# Defining acceptable standards in EQA

- Acceptable standards depend on type of test
- We have to make those standards (= quality) into a numerical score (=quantity)
- Who sets the standards?
- What happens when standards are not met?
- Experience of running EQA improve standards

EQA aim: Poor performers are educated, not punished

CEQA

### **Quality Issues in PGD**

- Choice of techniques/probes
- · Technical preparation quality
- · Accuracy of analysis
- · Interpretation of significance of the result
- Information given in the report
- Turn round times (hours/days)
- · How does EQA assess this?



CEQA

## Prospective Assessment 2009/2010

EQA scheme distributes the same material to all participants and assesses their returns

- ✓ Allows fair comparison
- √ Assessors can agree correct answer to permit consistent marking
- ✓ Online or distribute samples?
- × Online cannot assess technical ability
- x Participants may give EQA material special priority

CE	QA	23	-
ſ -	131		

## Retrospective Assessment 2008 only

Assessment of material from reported cases submitted by participants

- ✓ Examines the real work of the laboratory
- ✓ Easy to set up online
- × Cannot make comparisons between laboratories because submitted cases are different
- x Does not always measure current practice
- × Heavy workload for assessors
- x Technical assessment practical given different probes and filters?

CE	QA
٢-	M
U	

# CEQA: Cytogenetics European Quality Assessment


- Set up with funding from EuroGentest 2005 June 2010
- Constitutional cytogenetic pilot EQA in 2006
- Submission in multiple languages
- 2008 pilots for PGD FISH and leukaemia cytogenetics

•	En	٠.	Optopu	at R	-	
Ir.	1	н		_	_	Ī

# CEQA: Cytogenetics European Quality Assessment

- EQAs offered in 2010
- Administration charge: £100 EQA: £200
- Blood
- · Amniotic Fluid
- CVS
- PGD FISH (blastomeres and polar bodies)
- · Haemato-oncology
- Pilot ArrayCGH (constitutional)






## **CEQA National Representatives**


- · One for each EU country
- · Provide a link between CEQA and laboratories
- Conduit for communication about CEQA
- Communicate areas where EQA required
- · National issues relevant to EQA process
- List available on Eurogentest website


www.eurogentest.org
---------------------


























## EQA 2009 summary Part A: Work up

- Robertsonian translocation
- · Reciprocal translocation
- Feedback


## EQA 2009 summary Part B: Analysis and reporting

- Robertsonian translocation
- Reciprocal translocation
- Feedback

## Participation in 2009

- Number Registered
- Number Participating
- Number participating part A & B

## Appeals 2009



#### **PGD/PGS 2009**

Ros Hastings - CEQA Co-ordinator

Edith Coonen Joyce Harper Paul Scriven



CEQA

## **CEQA Marking Criteria**

The final report must contain information that explains why the investigation is done, what the results are and what the consequences are for the patient

- Accurate analysis
- Written description which embryos abnormal/normal/fail etc
- Interpretation of results which embryos transferrable
- Professional/ISO Standards compliance doc control

CEQA 2000

<b>CEQA</b>	<b>Marking</b>	Criteria
-------------	----------------	----------

- Analysis = 3 (correct), 0 (wrong)
- Written description = 3 Summary = 1
  Clerical accuracy = 1
  Guidelines followed = 1
- Interpretation = 3

Up to 6 important components of report: deduct 0.5-1.0 marks for each missing

- Total maximum = 9
- Poor performance if critical error (i.e. 0 score in analysis or interpretation)

Components of interpretation determined by assessors

CEQA22

### **CEQA Marking Criteria**

• Analysis = 3 (correct), 0 (wrong)

Analysis incorrect = 0

Partially correct = 1 or 2 points deducted Inappropriate test = 1 or 2 points deducted Insufficient analysis = 1 point deducted

Written description = 3

Inappropriate /incomplete work up = 1 point deducted No mention which embryos were normal/abnormal/fail etc = 1 or 2 points deducted

Not following Professional Guidelines = 1 point deducted

CEQA

### **CEQA Marking Criteria**

Interpretation=3 Assessors decide components of interpretation Deduct 0.5-1.0 marks for component each missing

Workup sheets:

Inappropriate limitation of tests

Inappropriate polymorphic probe used Inappropriate follow up Inappropriate risk assessment

Internal Report:

Not all embryos reported

No mention whether normal/abnormal/fail etc

No clear indication which embryos should be transferred External report (to PGD clinic):

No clear indication which embryos are normal/abnormal No clear indication which embryos should be transferred

Inappropriate directive advice for e.g. PND

Inappropriate follow up requested

C E C A Storet Erro

#### **Poor Performance**

- Error or omission with potential serious clinical consequence
- 2. Non-participation
- 3. Non-compliance: repeated warnings for the same omission or oversight
- Agreed by Steering Committee and assessors
- Laboratory may appeal
- Laboratory issued with a letter and asked what changes have been made

CEQAST

_			
_			
_			
_			
_			

### **Poor Performance**

Examples in PGD may be:

- Incorrect analysis or interpretation of FISH signals
- Incomplete or incorrect interpretation resulting in an incorrect diagnosis/transfer
- ➤ Failure to recognise all the possible chromosome constitutions underlying the FISH signal pattern e.g. normal vs unbalanced translocation segregants

CEQA

#### **CEQA: 2009**

- Individual Laboratory Report with scores
- · Summary letter
- · Annual report
- Participation AND performance certificates

CEQA 200

#### **CEQA -2010**

- PGD 2 parts
- ➤ Part A: workup case scenarios
- ➤ Part B: analysis of embryos
- ➤Blastomeres and polar bodies
- Future? ArrayCGH EQA expand to include PGD

CEQAST

## **Acknowledgements**

Ros Hastings: CEQA Scheme Organiser,

Bettina Quellhorst-Pawley: CEQA Quality Manager and Administrator

> Assessors PGD: Edith Coonen Joyce Harper Paul Scriven

Steering Committee PGD: Joyce Harper

#### Contact



web: www.ceqa-cyto.eu

email: eurogentest@orh.nhs.uk

Address:

Women's Centre, John Radcliffe Hospital, OXFORD, OX3 9DU. UK